{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:08:32Z","timestamp":1788779312161,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neuronopathic Gaucher disease (GD types II and III) represents rare and severe phenotypes of glucocerebrosidase deficiency, characterized by neurological involvement and variable systemic manifestations. Data on clinical presentation and genotype\u2013phenotype patterns in Eastern European populations remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective cohort study of 92 patients with confirmed Gaucher disease followed at the National Children\u2019s Specialized Hospital \u201cOkhmatdyt\u201d (Kyiv, Ukraine) between 2001 and 2024. Among them, 4 patients had type II and 6 had type III GD. Diagnosis was established by measurement of leukocyte \u03b2-glucocerebrosidase activity and molecular analysis of the\n                      <jats:italic>GBA1<\/jats:italic>\n                      gene. Clinical, laboratory, and imaging data were analyzed descriptively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Type II GD presented in early infancy, with symptom onset from birth to 5\u2009months of age (mean age at onset 2.8\u2009\u00b1\u20092.6\u2009months) and was diagnosed between 5 and 9\u2009months of age (mean 7.0\u2009\u00b1\u20092.3\u2009months). Initial manifestations included cytopenias, splenomegaly, failure to thrive, and ichthyosiform dermatitis. Hepatomegaly was uncommon at onset, but hepatosplenomegaly was documented in all patients at diagnosis, followed by rapid neurological regression and death by 14\u2009months of age. Type III GD had a mean age at onset of 2.3\u2009\u00b1\u20091.66\u2009years and a mean age at diagnosis of 13.8\u2009\u00b1\u200916.87\u2009years, reflecting substantial diagnostic delay. Oculomotor abnormalities were the most frequent presenting manifestations (83%). At diagnosis, all patients exhibited hepatosplenomegaly, cytopenias, and neurological involvement, while liver function remained preserved. Across both phenotypes, GBA1 variant combinations included genotypes predicted to result in very low or absent residual glucocerebrosidase activity, as well as genotypes predicted to retain some residual activity. Severe clinical courses were observed even in patients whose genotypes were predicted to retain residual enzyme activity, suggesting that predicted residual activity alone does not reliably explain clinical severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this Ukrainian cohort, neuronopathic GD demonstrated distinct clinical trajectories, with rapidly progressive infantile disease in type II and heterogeneous presentation with marked diagnostic delay in type III. Hepatosplenomegaly was a common systemic feature during disease progression, but should not be interpreted as an isolated stratifying sign. Its presence, particularly in combination with early or progressive neurological manifestations, should raise suspicion of neuronopathic GD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04578-x","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T09:54:01Z","timestamp":1788170041000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical and genetic landscape of neuronopathic gaucher disease in Ukraine: hepatosplenomegaly and diagnostic delay"],"prefix":"10.1186","volume":"21","author":[{"given":"Nataliia","family":"Samonenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliia","family":"Olkhovych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olena","family":"Okhotnikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliia","family":"Gorovenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"4578_CR1","unstructured":"Hughes DA, Pastores GM. Gaucher disease. In: Mp A, Feldman J, Gm M, et al. In: editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993\u20132024 [updated 2023 Dec 7]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1269\/.."},{"issue":"1","key":"4578_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13023-023-02760-z","volume":"18","author":"A Pession","year":"2023","unstructured":"Pession A, Di Rocco M, Venturelli F, Tappino B, Morello W, Santoro N, et al. GAU-PED study for early diagnosis of gaucher disease in children with splenomegaly and cytopenia. Orphanet J Rare Dis. 2023;18(1):151. https:\/\/doi.org\/10.1186\/s13023-023-02760-z.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"4578_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/diseases5010010","volume":"5","author":"T Roshan Lal","year":"2017","unstructured":"Roshan Lal T, Sidransky E. The spectrum of neurological manifestations associated with gaucher disease. Diseases. 2017;5(1):10. https:\/\/doi.org\/10.3390\/diseases5010010.","journal-title":"Diseases"},{"issue":"3","key":"4578_CR4","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ymgme.2004.04.011","volume":"82","author":"K Wong","year":"2004","unstructured":"Wong K, Sidransky CE, Verma A, Mixon T, Sandberg GD, Wakefield LK, et al. Neuropathology provides clues to the pathophysiology of gaucher disease. Mol Genet Metab. 2004;82(3):192\u2013207. https:\/\/doi.org\/10.1016\/j.ymgme.2004.04.011.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"4578_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ymgme.2021.01.002","volume":"132","author":"EC Daykin","year":"2021","unstructured":"Daykin EC, Ryan E, Sidransky E. Diagnosing neuronopathic gaucher disease: new considerations and challenges in assigning gaucher phenotypes. Mol Genet Metab. 2021;132(2):49\u201358. https:\/\/doi.org\/10.1016\/j.ymgme.2021.01.002.","journal-title":"Mol Genet Metab"},{"key":"4578_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ymgmr.2017.10.011","volume":"14","author":"IVD Schwartz","year":"2018","unstructured":"Schwartz IVD, G\u00f6ker-Alpan \u00d6, Kishnani PS, Zimran A, Renault L, Panahloo Z, et al. Characteristics of 26 patients with type 3 gaucher disease: a descriptive analysis from the gaucher outcome survey. Mol Genet Metab Rep. 2018;14:73\u201379. https:\/\/doi.org\/10.1016\/j.ymgmr.2017.10.011.","journal-title":"Mol Genet Metab Rep"},{"issue":"2","key":"4578_CR7","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ymgme.2014.11.008","volume":"114","author":"K Weiss","year":"2015","unstructured":"Weiss K, Gonzalez AN, Lopez G, Pedoeim L, Groden C, Sidransky E. The clinical management of type 2 gaucher disease. Mol Genet Metab. 2015;114(2):110\u201322. https:\/\/doi.org\/10.1016\/j.ymgme.2014.11.008.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"4578_CR8","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/joim.20114","volume":"298","author":"F Camou","year":"2025","unstructured":"Camou F, Berger MG. Gaucher disease, state of the art and perspectives. J Intern Med. 2025;298(3):155\u201372. https:\/\/doi.org\/10.1111\/joim.20114.","journal-title":"J Intern Med"},{"issue":"2","key":"4578_CR9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ymgme.2020.12.291","volume":"132","author":"GA Grabowski","year":"2021","unstructured":"Grabowski GA, Antommaria AHM, Kolodny EH, Mistry PK. Gaucher disease: basic and translational science needs for more complete therapy and management. Mol Genet Metab. 2021;132(2):59\u201375. https:\/\/doi.org\/10.1016\/j.ymgme.2020.12.291.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"4578_CR10","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s13023-022-02378-7","volume":"17","author":"A Donald","year":"2022","unstructured":"Donald A, Bj\u00f6rkvall CK, Vellodi A, Cox TM, Hughes D, Jones SA, et al. Thirty-year clinical outcomes after haematopoietic stem cell transplantation in neuronopathic gaucher disease. Orphanet J Rare Dis. 2022;17(1):158. https:\/\/doi.org\/10.1186\/s13023-022-02378-7.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"4578_CR11","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1002\/jimd.12235","volume":"43","author":"R Schiffmann","year":"2020","unstructured":"Schiffmann R, Sevigny J, Rolfs A, Davies EH, Goker-Alpan O, Abdelwahab M, et al. The definition of neuronopathic gaucher disease. J Inher Metab Disea. 2020;43(5):1056\u201359. https:\/\/doi.org\/10.1002\/jimd.12235.","journal-title":"J Inher Metab Disea"},{"issue":"5","key":"4578_CR12","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/humu.20676","volume":"29","author":"KS Hruska","year":"2008","unstructured":"Hruska KS, LaMarca ME, Scott CR, Sidransky E. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat. 2008;29(5):567\u201383. https:\/\/doi.org\/10.1002\/humu.20676.","journal-title":"Hum Mutat"},{"issue":"8","key":"4578_CR13","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/ajh.20908","volume":"82","author":"PK Mistry","year":"2007","unstructured":"Mistry PK, Sadan S, Yang R, Yee J, Yang M. Consequences of diagnostic delays in type 1 gaucher disease: the need for greater awareness among hematologists\u2013oncologists and an opportunity for early diagnosis and intervention. Am J Hematol. 2007;82(8):697\u2013701. https:\/\/doi.org\/10.1002\/ajh.20908.","journal-title":"Am J Hematol"},{"issue":"12","key":"4578_CR14","doi-asserted-by":"publisher","first-page":"6615","DOI":"10.3390\/ijms25126615","volume":"25","author":"E Pavan","year":"2024","unstructured":"Pavan E, Peruzzo P, Cattarossi S, Bergamin N, Bordugo A, Sechi A, et al. Deficiency of glucocerebrosidase activity beyond gaucher disease: PSAP and LIMP-2 dysfunctions. IJMS. 2024;25(12):6615. https:\/\/doi.org\/10.3390\/ijms25126615.","journal-title":"IJMS"},{"issue":"7","key":"4578_CR15","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1093\/qjmed\/hcw002","volume":"109","author":"MA Torralba","year":"2016","unstructured":"Torralba MA, Olivera S, Bureo JC, Dalmau J, Nu\u00f1ez R, Le\u00f3n P, et al. Residual enzymatic activity as a prognostic factor in patients with gaucher disease type 1: correlation with Zimran and GAUSS-I index and the severity of bone disease. QJM. 2016;109(7):449\u201352. https:\/\/doi.org\/10.1093\/qjmed\/hcw002.","journal-title":"QJM"},{"issue":"18","key":"4578_CR16","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1001\/archinte.160.18.2835","volume":"160","author":"J Charrow","year":"2000","unstructured":"Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, et al. The gaucher registry: demographics and disease characteristics of 1698 patients with gaucher disease. Arch Intern Med. 2000;160(18):2835\u201343. https:\/\/doi.org\/10.1001\/archinte.160.18.2835.","journal-title":"Arch Intern Med"},{"issue":"1","key":"4578_CR17","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3390\/jcm12010085","volume":"12","author":"G Castillon","year":"2022","unstructured":"Castillon G, Chang SC, Moride Y. Global incidence and prevalence of gaucher disease: a targeted literature review. JCM. 2022;12(1):85. https:\/\/doi.org\/10.3390\/jcm12010085.","journal-title":"JCM"},{"issue":"4","key":"4578_CR18","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s10545-009-9009-6","volume":"33","author":"A Tylki-Szyma\u0144ska","year":"2010","unstructured":"Tylki-Szyma\u0144ska A, Vellodi A, El-Beshlawy A, Cole JA, Kolodny E. Neuronopathic gaucher disease: demographic and clinical features of 131 patients enrolled in the international collaborative gaucher group neurological outcomes subregistry. J Inher Metab Disea. 2010;33(4):339\u201346. https:\/\/doi.org\/10.1007\/s10545-009-9009-6.","journal-title":"J Inher Metab Disea"},{"issue":"1","key":"4578_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.braindev.2005.04.005","volume":"28","author":"C Mignot","year":"2006","unstructured":"Mignot C, Doummar D, Maire I, de Villemeur TB. French type 2 gaucher disease study group. Type 2 gaucher disease: 15 new cases and review of the literature. Brain Dev. 2006;28(1):39\u201348. https:\/\/doi.org\/10.1016\/j.braindev.2005.04.005.","journal-title":"Brain Dev"},{"issue":"2","key":"4578_CR20","doi-asserted-by":"publisher","first-page":"109124","DOI":"10.1016\/j.ymgme.2025.109124","volume":"145","author":"A Donald","year":"2025","unstructured":"Donald A, Brothwell S, Cabello BM, Ehrstedt C, Fern\u00e1ndez-Fructuoso JR, Fern\u00e1ndez-Mar\u00edn E, et al. 250 cases of \u201ctype 2 gaucher disease\u201d: a novel system of clinical categorisation and evidence of genotype: phenotype correlation. Mol Genet Metab. 2025;145(2):109124. https:\/\/doi.org\/10.1016\/j.ymgme.2025.109124.","journal-title":"Mol Genet Metab"},{"issue":"5","key":"4578_CR21","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1002\/jimd.12749","volume":"47","author":"O Goker-Alpan","year":"2024","unstructured":"Goker-Alpan O, Ivanova MM. Neuronopathic gaucher disease: rare in the West, common in the east. J Inher Metab Disea. 2024;47(5):917\u201334. https:\/\/doi.org\/10.1002\/jimd.12749.","journal-title":"J Inher Metab Disea"},{"issue":"1","key":"4578_CR22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/01.gim.0000196443.42899.25","volume":"8","author":"A Tylki-Szyma\u0144ska","year":"2006","unstructured":"Tylki-Szyma\u0144ska A, Keddache M, Grabowski GA. Characterization of neuronopathic gaucher disease among ethnic poles. Genet Med. 2006;8(1):8\u201316. https:\/\/doi.org\/10.1097\/01.gim.0000196443.42899.25.","journal-title":"Genet Med"},{"issue":"1","key":"4578_CR23","doi-asserted-by":"publisher","first-page":"15358","DOI":"10.1038\/s41598-019-51976-2","volume":"9","author":"M Andr\u00e9asson","year":"2019","unstructured":"Andr\u00e9asson M, Solders G, Bj\u00f6rkvall CK, Machaczka M, Svenningsson P. Polyneuropathy in gaucher disease type 1 and 3 \u2013 a descriptive case series. Sci Rep. 2019;9(1):15358. https:\/\/doi.org\/10.1038\/s41598-019-51976-2.","journal-title":"Sci Rep"},{"issue":"4","key":"4578_CR24","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.ymgme.2018.02.004","volume":"123","author":"A Tylki-Szyma\u0144ska","year":"2018","unstructured":"Tylki-Szyma\u0144ska A, Szyma\u0144ska-Ro\u017cek P, Hasi\u0144ski P, \u0141ugowska A. Plasma chitotriosidase activity versus plasma glucosylsphingosine in wide spectrum of gaucher disease phenotypes \u2013 a statistical insight. Mol Genet Metab. 2018;123(4):495\u2013500. https:\/\/doi.org\/10.1016\/j.ymgme.2018.02.004.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"4578_CR25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.7124\/bc.000940","volume":"33","author":"NV Olkhovych","year":"2017","unstructured":"Olkhovych NV, Nedoboy AM, Pichkur NO, Gorovenko NH. Analysis of mutations in GBA gene in Ukrainian patients with gaucher disease. Biopolym Cell. 2017;33(1):34\u201347. https:\/\/doi.org\/10.7124\/bc.000940.","journal-title":"Biopolym Cell"},{"key":"4578_CR26","unstructured":"Olkhovych N. Molecular and genetic principles of lysosomal pathology formation in gaucher disease in the Ukrainian population. 2021 [dissertation]. Kyiv: Shupyk National Healthcare University of Ukraine."},{"issue":"10","key":"4578_CR27","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nrneurol.2013.163","volume":"9","author":"R-MN Boustany","year":"2013","unstructured":"Boustany R-MN. Lysosomal storage diseases\u2014the horizon expands. Nat Rev Neurol. 2013;9(10):583\u201398. https:\/\/doi.org\/10.1038\/nrneurol.2013.163.","journal-title":"Nat Rev Neurol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04578-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04578-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04578-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:13:23Z","timestamp":1788776003000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04578-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4578"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04578-x","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"assertion":[{"value":"7 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the National Children\u2019s Specialized Hospital \u201cOkhmatdyt\u201d of the Ministry of Health of Ukraine. Written informed consent for diagnostic procedures, clinical assessments, and use of anonymized data for research and publication was obtained from all participants or their legal guardians prior to inclusion in the institutional database.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients and their parents or legal representatives provided signed and dated written informed consent for diagnostic evaluation and for publication of de-identified clinical data, in accordance with the legislation of Ukraine and applicable national data protection requirements.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"314"}}